ESALY - Eisai Co. Ltd. (ESALF) Management on Q3 2021 Results - Earnings Call Transcript
Eisai Co. Ltd. (ESALF) Q3 2021 Earnings Conference Call February 03, 2021 02:30 AM ET Company Participants Ryohei Yanagi - EVP & CFO Ivan Cheung - SVP & President of Neurology Business Group Takashi Owa - Chief Medicine Creation Officer & Chief Discovery Officer Oncology Terushige Iike - SVP & President of Oncology Business Group Conference Call Participants Motoya Kohtani - Nomura Securities Hidemaru Yamaguchi - Citigroup Seiji Wakao - JPMorgan Kazuaki Hashiguchi - Daiwa Securities Shinichiro Muraoka - Morgan Stanley Presentation Ryohei Yanagi Now this is Yanagi, CFO, speaking. I would like to report to you on the financial part. Please turn to Page 1. Here, you can see the consolidated statement of income for the third quarter cumulative numbers for FY 2020. Even though there was impact by COVID-19 pandemic, we could achieve increase in revenue top line. Revenue was JPY 498.3 billion, up 3% from a year
For further details see:
Eisai Co., Ltd. (ESALF) Management on Q3 2021 Results - Earnings Call Transcript